Maravai LifeSciences (NASDAQ:MRVI) Price Target Lowered to $5.00 at Morgan Stanley

Maravai LifeSciences (NASDAQ:MRVI) had its price target reduced by Morgan Stanley from $7.00 to $5.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an equal weight rating on the stock.

Several other equities analysts also recently issued reports on MRVI. UBS Group reduced their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating for the company in a report on Friday, March 21st. Robert W. Baird lowered shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $9.00 to $3.00 in a research note on Wednesday, February 26th. Bank of America dropped their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their price target for the company from $7.00 to $4.25 in a report on Thursday, December 5th. Finally, Guggenheim assumed coverage on Maravai LifeSciences in a research report on Thursday, December 19th. They issued a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $7.59.

Maravai LifeSciences Trading Up 2.7 %

Shares of NASDAQ MRVI opened at $2.30 on Tuesday. Maravai LifeSciences has a 12-month low of $2.07 and a 12-month high of $11.56. The company has a market cap of $580.81 million, a price-to-earnings ratio of -1.40 and a beta of -0.08. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The stock’s 50 day simple moving average is $3.86 and its 200 day simple moving average is $5.70.

Insider Buying and Selling at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the completion of the sale, the general counsel now owns 167,618 shares in the company, valued at $843,118.54. This represents a 12.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.63% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Maravai LifeSciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Performa Ltd US LLC boosted its position in shares of Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after purchasing an additional 4,300 shares in the last quarter. FNY Investment Advisers LLC boosted its holdings in Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after buying an additional 6,000 shares in the last quarter. Farther Finance Advisors LLC grew its position in Maravai LifeSciences by 3,541.4% in the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock worth $56,000 after buying an additional 9,916 shares during the last quarter. Cibc World Markets Corp bought a new position in shares of Maravai LifeSciences in the fourth quarter valued at $56,000. Finally, Atria Investments Inc acquired a new stake in shares of Maravai LifeSciences during the 4th quarter valued at $58,000. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.